Navigation Links
Global Standardization for Alzheimer's Biomarkers Moves a Major Step Closer to Reality
Date:8/11/2011

NEW YORK, Aug. 11, 2011 /PRNewswire/ -- Citeline, an Informa business unit, and the world's leading research authority on pharmaceutical clinical trials recently reviewed the findings from the 14th International Conference on Alzheimer's Disease (ICAD 2011/AAIC 2011) July 16-21, 2011, noting that while pharma continues to develop beta amyloid targeting drugs, amyloid targets are moving ahead in terms of biomarkers and early warning for risk of Alzheimer's.

According to Dr. Revati Tatake, CNS Analyst at Citeline, noteworthy among the biomarkers/genomics-focused on-going studies were multiple studies under the worldwide initiative, "Alzheimer's Disease Neuroimaging Initiative (ADNI)", spearheaded by the Alzheimer's Association in an effort to globally standardize Alzheimer's biomarkers, and the "Dominantly Inherited Alzheimer's Network (DIAN)" study.  The results from three ADNI studies from different countries suggested that a worldwide ADNI data set can be used for combined analysis of APOE-e4 on amyloid deposition, a step closer to the goal of global standardization of biomarkers. The DIAN study has a slightly different focus and indicated that abnormal levels of CSF amyloid-beta42 and tau protein, brain chemistry and imaging changes can be detected at least 10 years and up to 20 years before the expected onset of Alzheimer's in the subjects with genetic predisposition.

"The progress in Alzheimer's biomarkers/genomics field is especially significant as several clinical studies involving anti-Alzheimer's drugs are investigating CSF/plasma/brain amyloid-beta levels as one of the major efficacy biomarkers and using APOE-e4 genotype for stratifying patients for the treatment," commented Dr. Tatake.  In fact out of the 40 abstracts involving pipeline drugs presented at this meeting, 14 trials contained analysis of biomarker and/or genomic parameters.

A late breaking report concerning long-term safety results of an ongoing Phase II trial of bapineuzumab beyond 78 weeks is worth mentioning.  The long term safety data that bapineuzumab was generally well-tolerated and side-effects tended to be mild and less frequent over time are certainly encouraging, as bapineuzumab is one of the most advanced anti- beta amyloid antibodies that are in clinical development.  Bapineuzumab, jointly developed by Pfizer and J&J, is currently in several ongoing pivotal trials.

Among other approaches targeting the beta amyloid pathway, AFFiRiS/GSK presented safety data for active immunotherapy approach by AFFITOPE AD02.  Bristol-Myers Squibb and Chiesi presented safety and tolerably results of their gamma secretase inhibitors, avagacestat (BMS-708163) and CHF-5074, respectively.   The safety results of gamma secretase inhibitors are particularly important in light of termination of pivotal trials of Lilly's gamma secretase inhibitor, semagacestat, for safety reasons. "It remains to be seen if Lilly's termination of semagacestat has impacted/will impact the course for other gamma secretase inhibitors that are in clinical development," added Dr. Tatake.

About Citeline

Citeline (www.citeline.com) provides the world's most comprehensive real-time R&D intelligence to the pharmaceutical industry, covering global clinical trial, investigator and drug intelligence. Our data is drawn from over 18,000 unique sources and analyzed by the industry's largest team – over 250 full-time expert analysts and editors.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Julie McKenna
Citeline Marketing Manager
617.415.1981


'/>"/>
SOURCE Citeline
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017
2. Generic Drugs in Consumer Health Global Overview 2011
3. Global Health Ventures August 4th Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
4. Spaulding Clinical Announces New Joint Partnership for Global Studies with Eurofins Optimed Clinical Research
5. Global GMP Guidelines Available in Online GMP Library
6. Robbins & Myers to Present at Jefferies 2011 Global Industrial Conference
7. Global Pharm Holdings Group Completes Acquisition of Pacific Asia Pharm Investment Group Co., Ltd.
8. Robertson Global Health Solutions Announces Progress Towards Commercial Venture with LifeSense
9. SI-BONE Announces Global Clinical Strategy for Minimally Invasive iFuse Sacroiliac Joint Fusion
10. Global Health Ventures to Present Live, Online at RetailInvestorConferences.com on August 4th
11. Global Mercury Treaty May Include Ban on Mercury in Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
Breaking Medicine News(10 mins):